Profile data is unavailable for this security.
About the company
QuidelOrtho Corporation provides in vitro diagnostics, developing and manufacturing intelligent solutions. The Company specializes in immunoassay and molecular testing, clinical chemistry and transfusion medicine. Its business units include labs, molecular diagnostics, point of care and transfusion medicine. Under the labs business unit, its product categories include virology & bioassays, specialty products, VITROS platform and immunodiagnostics. Under the molecular diagnostics business unit, its product categories include Lyra, Solana and Savanna. Under the point of care business unit, its product categories include rapid immunoassay and cardiometabolic immunoassay. Under the transfusion medicine business unit, its product categories include immunohematology and donor screening. It provides diagnostic testing solutions under various brand names, including AdenoPlus, BIOVUE, FreshCells, InflammaDry, Lyra, MeterPro, MicroVue, Ortho, Ortho Clinical Diagnostics and Ortho Optix.
- Revenue in USD (TTM)2.73bn
- Net income in USD-1.13bn
- Incorporated2021
- Employees6.50k
- LocationQuidelOrtho Corp9975 Summers Ridge RoadSAN DIEGO 92121United StatesUSA
- Phone+1 (858) 552-1100
- Fax+1 (858) 453-4338
- Websitehttps://www.quidelortho.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pulse Biosciences Inc | 350.00k | -72.78m | 1.22bn | 116.00 | -- | 15.10 | -- | 3,486.87 | -1.08 | -1.08 | 0.0052 | 1.19 | 0.0031 | -- | -- | 3,017.24 | -64.12 | -74.23 | -69.64 | -82.45 | -54.00 | -- | -20,794.57 | -11,780.43 | 10.51 | -- | 0.00 | -- | -- | -- | -35.82 | -- | -5.35 | -- |
| Adapthealth Corp | 3.24bn | -70.27m | 1.28bn | 10.90k | -- | 0.8385 | 3.86 | 0.3937 | -0.5224 | -0.5224 | 23.84 | 11.21 | 0.7372 | 17.60 | 8.33 | 297,693.30 | -1.50 | -1.84 | -1.76 | -2.08 | 21.07 | 20.27 | -2.04 | -2.74 | 0.8109 | 1.96 | 0.5393 | -- | -0.4943 | 25.16 | -185.55 | -- | 57.26 | -- |
| Iradimed Corp | 83.81m | 22.48m | 1.33bn | 160.00 | 59.62 | 14.02 | 78.86 | 15.83 | 1.75 | 1.75 | 6.52 | 7.44 | 0.8094 | -- | -- | -- | 21.71 | 18.06 | 23.86 | 20.21 | 76.75 | 76.85 | 26.82 | 25.51 | -- | -- | -- | -- | 14.43 | 21.45 | 16.88 | 108.61 | -- | -- |
| Kestra Medical Technologies Ltd | 74.26m | -138.79m | 1.34bn | 330.00 | -- | 7.19 | -- | 18.01 | -2.76 | -2.76 | 1.47 | 3.19 | 0.4034 | -- | 9.40 | 225,027.30 | -71.43 | -122.23 | -92.37 | -192.35 | 46.40 | -- | -177.06 | -342.51 | -- | -116.72 | 0.2033 | -- | 115.05 | -- | -25.08 | -- | 150.61 | -- |
| Conmed Corp | 1.37bn | 47.06m | 1.34bn | 3.90k | 28.69 | 1.30 | 11.03 | 0.9736 | 1.51 | 1.51 | 44.20 | 33.36 | 0.5936 | 1.78 | 5.66 | 352,493.60 | 2.03 | 2.11 | 2.33 | 2.41 | 54.59 | 54.98 | 3.42 | 3.78 | 1.01 | 3.30 | 0.447 | 51.06 | 5.18 | 9.77 | -64.47 | 37.66 | 8.76 | -5.59 |
| Enovis Corp | 2.25bn | -1.18bn | 1.45bn | 7.80k | -- | 0.971 | -- | 0.644 | -20.69 | -20.72 | 39.39 | 26.05 | 0.5256 | 1.66 | 5.29 | 288,137.50 | -27.63 | -7.98 | -31.84 | -9.05 | 58.16 | 56.87 | -52.57 | -24.34 | 1.04 | 1.06 | 0.465 | -- | 6.66 | -6.05 | -42.80 | -- | 11.45 | -- |
| Quidelortho Corp | 2.73bn | -1.13bn | 1.46bn | 6.50k | -- | 0.7594 | -- | 0.5356 | -16.66 | -16.66 | 40.25 | 28.28 | 0.4478 | 2.62 | 7.12 | 420,030.80 | -18.56 | -6.45 | -22.13 | -7.39 | 46.67 | 53.89 | -41.45 | -14.40 | 0.9002 | 0.3677 | 0.5798 | -- | -1.89 | 10.44 | 44.84 | -- | 23.72 | -- |
| Procept Biorobotics Corp | 308.05m | -95.57m | 1.48bn | 888.00 | -- | 4.04 | -- | 4.81 | -1.72 | -1.72 | 5.55 | 6.50 | 0.5912 | 1.76 | 3.69 | 346,907.70 | -18.34 | -23.13 | -20.70 | -25.70 | 63.70 | 58.76 | -31.02 | -56.52 | 5.77 | -- | 0.1236 | -- | 37.22 | 109.04 | -4.55 | -- | 109.29 | -- |
| Novocure Ltd | 655.35m | -136.23m | 1.51bn | 1.61k | -- | 4.39 | -- | 2.31 | -1.22 | -1.22 | 5.88 | 3.03 | 0.6409 | 4.35 | 8.01 | 408,319.60 | -13.32 | -11.74 | -25.57 | -15.63 | 74.73 | 76.71 | -20.79 | -23.31 | 2.71 | -- | 0.3642 | -- | 8.28 | 5.80 | 19.21 | -- | 12.23 | -- |
| AxoGen Inc | 225.21m | -15.70m | 1.55bn | 622.00 | -- | 10.93 | -- | 6.87 | -0.3413 | -0.3413 | 4.77 | 2.73 | 1.06 | 1.53 | 8.96 | 362,070.80 | -7.38 | -10.17 | -8.46 | -11.70 | 74.31 | 77.27 | -6.97 | -12.34 | 3.31 | -0.9786 | 0.2732 | -- | 20.21 | 14.93 | -57.60 | -- | -24.36 | -- |
| UFP Technologies Inc | 602.80m | 68.31m | 1.57bn | 4.85k | 23.17 | 3.69 | 17.88 | 2.60 | 8.76 | 8.76 | 77.29 | 54.95 | 0.9389 | 4.96 | 7.19 | 124,390.60 | 10.64 | 10.57 | 12.06 | 12.07 | 28.27 | 27.60 | 11.33 | 11.12 | 1.52 | 9.46 | 0.2422 | 0.00 | 19.50 | 27.43 | 15.82 | 38.57 | 24.23 | -- |
| AtriCure Inc | 534.53m | -11.45m | 1.57bn | 1.35k | -- | 3.18 | 172.52 | 2.93 | -0.241 | -0.241 | 11.19 | 9.88 | 0.8461 | 1.74 | 8.42 | 395,946.70 | -1.81 | -2.67 | -2.07 | -2.98 | 74.98 | 74.88 | -2.14 | -4.13 | 2.99 | -6.75 | 0.1232 | -- | 14.88 | 20.95 | 74.39 | -- | 23.40 | -- |
| Tandem Diabetes Care Inc | 1.01bn | -204.71m | 1.62bn | 2.50k | -- | 10.45 | -- | 1.60 | -3.07 | -3.07 | 15.08 | 2.27 | 1.10 | 3.37 | 7.25 | 405,894.40 | -22.15 | -12.88 | -30.13 | -16.00 | 53.81 | 52.12 | -20.17 | -14.32 | 2.02 | -6.00 | 0.6699 | -- | 7.93 | 15.26 | -113.18 | -- | -9.19 | -- |
| Artivion Inc | 441.33m | 9.76m | 1.85bn | 1.80k | 194.39 | 4.12 | 57.38 | 4.19 | 0.1987 | 0.1987 | 9.44 | 9.37 | 0.5273 | 1.82 | 5.22 | 245,183.30 | 1.17 | -1.72 | 1.30 | -1.86 | 64.40 | 64.69 | 2.21 | -3.80 | 2.62 | 1.44 | 0.3278 | -- | 13.59 | 11.75 | 173.17 | -- | 39.74 | -- |
| Omnicell Inc | 1.18bn | 2.05m | 1.85bn | 3.58k | 944.01 | 1.49 | 22.64 | 1.56 | 0.0432 | 0.0432 | 25.70 | 27.36 | 0.5786 | 7.19 | 5.01 | 330,962.30 | 0.1002 | 0.7331 | 0.1357 | 0.9767 | 42.49 | 44.88 | 0.1732 | 1.32 | 1.22 | -- | 0.1198 | 0.00 | 6.53 | 5.84 | -83.62 | -42.34 | 1.93 | -- |
| Inspire Medical Systems Inc | 911.98m | 145.42m | 1.88bn | 1.33k | 13.24 | 2.41 | 11.80 | 2.06 | 4.97 | 4.97 | 30.75 | 27.33 | 1.06 | 1.18 | 8.57 | 684,156.80 | 16.95 | 3.09 | 19.00 | 3.48 | 85.39 | 84.83 | 15.95 | 3.05 | 4.56 | -- | 0.00 | 0.00 | 13.60 | 51.21 | 171.77 | -- | 73.41 | -- |
Data as of Mar 03 2026. Currency figures normalised to QuidelOrtho Corp's reporting currency: US Dollar USD
75.69%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| T. Rowe Price Investment Management, Inc.as of 31 Dec 2025 | 11.83m | 17.43% |
| BlackRock Fund Advisorsas of 31 Dec 2025 | 9.46m | 13.93% |
| The Vanguard Group, Inc.as of 31 Dec 2025 | 7.00m | 10.31% |
| Fidelity Management & Research Co. LLCas of 31 Dec 2025 | 5.37m | 7.91% |
| Rubric Capital Management LPas of 31 Dec 2025 | 3.78m | 5.56% |
| Invesco Advisers, Inc.as of 31 Dec 2025 | 3.18m | 4.68% |
| Newtyn Management LLCas of 31 Dec 2025 | 3.01m | 4.44% |
| Dimensional Fund Advisors LPas of 31 Dec 2025 | 2.73m | 4.03% |
| SSgA Funds Management, Inc.as of 31 Dec 2025 | 2.70m | 3.98% |
| American Century Investment Management, Inc.as of 31 Dec 2025 | 2.33m | 3.43% |
More ▼
Data from 31 Dec 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
